Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
Date:1/31/2008

e made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litig
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Hologic Announces First Quarter Fiscal 2008 Operating Results
3. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
4. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
5. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
6. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Genelabs Technologies, Inc. Announces Resignation of President and CEO
9. CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board
10. BioHorizons Announces Agreement to Purchase Implant Logic Systems
11. AlphaVax Announces New CMV Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and ... in the first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by ... 2014, this course combines students from both universities and is taught on both ...
(Date:6/30/2015)... 2015  Today, Americord Registry, one of the fastest growing ... , a partner at Kirkland & Ellis LLP, as the ... - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about ... Martin Smithmyer , CEO of Americord. "He brings a ... will assist Americord,s growth and vision." Andrew ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... Dallas-based maker of neurotechnology research systems, announced the sale of its ... in 1983. , ... DALLAS (Business Wire EON) ... as it is called by many brain researchers after its inventor, ...
... defects, bulk crystalline materials never achieve their ideal strength; ... no room for defects. ("Nano" is short for nanometer, ... may approach ideal strength in their resistance to stress, ... withstand large internal strains before they fail. Overcoming this ...
... 20 The board of directors,of Eli Lilly and Company ... quarter of 2008 of $0.47 a share on outstanding common ... first three quarters of 2008 and,brings the total annual dividend ... payable December 10, 2008, to shareholders of record at,the close ...
Cached Biology Technology: Plexon Inc Delivers 500th "Harvey Box" : 25 Years of Neural Data Acquisition and Analysis Leads to 500th System Sale 2 Plexon Inc Delivers 500th "Harvey Box" : 25 Years of Neural Data Acquisition and Analysis Leads to 500th System Sale 3Engineering nanoparticles for maximum strength 2Engineering nanoparticles for maximum strength 3Engineering nanoparticles for maximum strength 4
(Date:6/16/2015)... YORK , June 16, 2015  With the ... world, security remains a top concern. The recent compromise ... confirms the need for strong authentication within government agencies. ... Token, a biometric one-time password (OTP) authenticator, has been ... Standards (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... previously communicated that it will amount to at least 340 ... Due to the rapid increase in market growth and orders ... previously communicated guidance that revenue for 2015 will exceed 1,500 ... amount to approximately 2,200 MSEK. Due to receipt ...
(Date:6/15/2015)... , June 15, 2015 A new ... Telstra reveals the majority of US consumers using mobile banking ... biometrics, such as fingerprint and voiceprint, instead of having to ... According to Telstra,s " Mobile Identity   -   The ... report, with smartphones now the primary channel used by Gen ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... to $10.3 million to help develop a new prosthetic arm that ... work is a key part of a U.S. Department of Defense ... for soldiers and potentially others whose arms were amputated. , "Imagine ... that allows you to feel both the outside world and your ...
... as saccharin with a sensory experience in which ... guided researchers to an increased understanding of how ... in an advance online publication in Nature, scientists ... certain artificial sweeteners, including sodium saccharin and acesulfame-K, ...
... to how bacteria that infect humans develop a resistance ... January 20 issue of the journal Science, McMaster University ... may be the key in identifying how and why ... future clinical problems, and testing new antibiotics. , Antibiotic ...
Cached Biology News:University of Utah to help build bionic arm 2University of Utah to help build bionic arm 3University of Utah to help build bionic arm 4University of Utah to help build bionic arm 5Sweet 'water taste' paradoxically predicts sweet taste inhibitors 2Researchers use dirt to stay one step ahead of antibiotic resistance 2Researchers use dirt to stay one step ahead of antibiotic resistance 3
... a recombinant protein that has been shown to ... preparation of cDNA by reverse transcription, in vitro ... RNA Safe Inhibitor tightly binds RNases in a ... eukaryotic RNases such as RNase A, RNase B, ...
... Natural and Recombinant RNasin Ribonuclease Inhibitors have ... inhibition of eukaryotic RNases of the neutral ... inhibitory effect by noncovalently binding to RNases ... for the binding of RNasin Ribonuclease Inhibitor ...
...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
Biology Products: